A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Recruiting now · Phase 3
Conditions studied: Ovarian Neoplasms, Ovarian Cancer
In brief
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Key facts
- Study ID
- NCT07318558
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 900
- Starts
- 2026-02-16
- Expected to finish
- 2033-02-25
- Last updated by the study team
- 2026-08-07
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085) — Orlando, Florida, United States (enrolling)
- Winship Cancer Institute of Emory University ( Site 0037) — Atlanta, Georgia, United States (enrolling)
- Illinois Cancer Specialists (ICS) ( Site 8009) — Arlington Heights, Illinois, United States (enrolling)
- Parkview Research Center at Parkview Regional Medical Center ( Site 0055) — Fort Wayne, Indiana, United States (enrolling)
- Women's Cancer Care ( Site 0018) — Covington, Louisiana, United States (enrolling)
- Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0060) — Scarborough, Maine, United States (enrolling)
- Maryland Oncology Hematology, P.A. ( Site 8002) — Columbia, Maryland, United States (enrolling)
- Nebraska Methodist Hospital ( Site 0004) — Omaha, Nebraska, United States (enrolling)
- University Of Nebraska Medical Center ( Site 0035) — Omaha, Nebraska, United States (enrolling)
- The Center of Hope ( Site 0025) — Reno, Nevada, United States (enrolling)
- Womens Cancer Care Associates, LLC ( Site 0023) — Albany, New York, United States (enrolling)
- University of Cincinnati Medical Center ( Site 0042) — Cincinnati, Ohio, United States (enrolling)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007) — Tulsa, Oklahoma, United States (enrolling)
- Women & Infants Hospital ( Site 0001) — Providence, Rhode Island, United States (enrolling)
- West Cancer Center and Research Institute ( Site 0013) — Germantown, Tennessee, United States (enrolling)
- University of Tennessee Medical Center ( Site 0087) — Knoxville, Tennessee, United States (enrolling)
- Hospital Aleman ( Site 2903) — Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina (enrolling)
- Instituto Alexander Fleming ( Site 2902) — Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina (enrolling)
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 2901) — Mar del Plata, Buenos Aires, Argentina (enrolling)
- Fundación Respirar ( Site 2912) — Buenos Aires, Buenos Aires F.D., Argentina (enrolling)
- Sanatorio Parque - Oncología ( Site 2911) — Rosario, Santa Fe Province, Argentina (enrolling)
- Instituto de Oncologia de Rosario ( Site 2909) — Rosario, Santa Fe Province, Argentina (enrolling)
- Hospital Britanico de Buenos Aires ( Site 2905) — CABA, Argentina (enrolling)
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 2907) — La Rioja, Argentina (enrolling)
- Mount Sinai Cancer Center ( Site 0029) — Miami Beach, Florida, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.